|
|
°ñ´Ù°øÁõ Ä¡·á : ¼¼°è ½ÃÀåÀÇ Àü¸Á Osteoporosis Therapeutics - A Global Market Perspective |
|
Pub Time : 2009/11 Published by : BizAcumen, Inc. |
| ¼¼°èÀÇ °ñ´Ù°øÁõ Ä¡·áÁ¦ ½ÃÀå µ¿Çâ¿¡ ´ëÇØ ºÐ¼®ÇÏ°í ¾÷°èÀÇ µ¿Çâ, Á¦Ç° °³¿ä, ÀÓ»ó ½ÇÇè µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ´ëÀÀ ¹× °¢±¹ ½ÃÀ庰 µ¿ÇâÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
°ñ´Ù°øÁõÀÇ »õ·Î¿î Ä¡·áÁ¦ Pipeline and Commercial Insight: Osteoporosis Novel agents to battle for payer acceptance |
|
Pub Time : 2009/07 Published by : Datamonitor |
| ¼¼°è 7´ë ½ÃÀå ¹× BRIC ±¹°¡(ºê¶óÁú, ·¯½Ã¾Æ, Àεµ, Áß±¹)ÀÇ È¯ÀÚ °³¿ä ¹× ¼¼°èÀÇ Áö¿ªº° ó¹æ µ¿Çâ, 2018³â±îÁöÀÇ ¸ÅÃâ ¿¹Ãø ±×¸®°í ½Å¾àÀÇ ¿¬±¸ °³¹ß µ¿ÇâÀ» ÀüÇØµå¸³´Ï´Ù. |
|
°ñ´Ù°øÁõ ½ÃÀå¿¡ ´ëÇÑ ¿¹Ãø Osteoporosis Market Forecast |
|
Pub Time : 2009/07 Published by : Datamonitor |
| °ñ´Ù°øÁõ Ä¡·áÁ¦ ½ÃÀåÀÇ ÇöȲ ¹× ÇâÈÄ ¿¹Ãø, ÇöÀç Ä¡·á¹ýÀÇ ¹ÌÃæÁ· ¿ä±¸, °³¹ßÁßÀÎ ¾àÁ¦, ¹Ì±¹, ÀϺ», ÇÁ¶û½º, µ¶ÀÏ, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ¿µ±¹ µî ÁÖ¿ä±¹°¡ÀÇ Ãâ½Ã ÀǾàǰ, Á¦³×¸¯ ÀǾàǰÀÇ 2018³â±îÁöÀÇ ¸Å»ó ¿¹Ãø µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. |
|
¹Ì±¹ÀÇ ´Ù¹ß¼º °ñ¼öÁ¾ Ä¡·á Multiple Myeloma Therapeutics |
|
Pub Time : 2009/04 Published by : Global Industry Analysts, Inc. |
| ¹Ì±¹ÀÇ ´Ù¹ß¼º °ñ¼öÁ¾ Ä¡·á ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, °ü·Ã ÀÓ»ó ±â¼ú ¹× ¾àÁ¦ °³¹ß µ¿Çâ, µ¿ ºÐ¾ßÀÇ ÇöȲ ¹× °úÁ¦, ÇâÈÄ Àü¸Á µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. |
|
Áß±¹ÀÇ °ñ´Ù°øÁõ Ä¡·áÁ¦ ½ÃÀå Chinese Markets for Osteoporosis Drugs |
|
Pub Time : 2009/04 Published by : Asia Market Information & Development Co. |
| Áß±¹ÀÇ °æÁ¦ µ¿Çâ, °ñ´Ù°øÁõ Ä¡·áÁ¦ ½ÃÀåÀÇ ÅõÀÚ È¯°æ, »ê¾÷ÀÇ ¹ßÀü, ¼ö¿ä¤ý°ø±Þ, »ê¾÷ ±¸Á¶, ½ÃÀå °æ·Î¤ýÁÖ¿ä ±â¾÷ µîÀ» »ó¼¼È÷ Á¶»çÇϰí 2003³â ¹× 2008³âÀÇ ½ÇÀû°ú 2013³â¤ý2018³âÀÇ Àå±â ¿¹ÃøÀ» ÀüÇØµå¸³´Ï´Ù. |
|
À¯·´ÀÇ »À¼ºÀå ¹× Ã´Ãß°íÁ¤ ÀÚ±ØÀåÄ¡ ½ÃÀå European Bone Growth and Spinal Fusion Stimulators Markets |
|
Pub Time : 2008/10 Published by : Frost & Sullivan |
| À¯·´ÀÇ »À¼ºÀå ¹× Ã´Ãß°íÁ¤ ÀÚ±ØÀåÄ¡ ½ÃÀå¿¡ ´ëÇØ ºÐ¼®ÇÏ°í ½ÃÀå Âü°¡ ±â¾÷ÀÌ Á÷¸éÇÑ °úÁ¦, °æÇÕ ±¸Á¶, ¼öÀÍ ¿¹Ãø, ¼ºÀå·ü ¹× Àü·« µîÀ» ÀüÇØµå¸³´Ï´Ù. |
|
°ñ´Ù°øÁõÀÇ Áø´Ü¡¤Ä¡·á¡¤Ã³¹æ µ¿Çâ Stakeholder Insight: Osteoporosis - Generic alendronate further establishes oral bisphosphonates as gold standard |
|
Pub Time : 2008/10 Published by : Datamonitor |
| ¼¼°è ÁÖ¿ä 7°³±¹ ½ÃÀåÀÇ °ñ´Ù°øÁõ Áø´Ü¡¤Ä¡·á¡¤Ã³¹æ µ¿Çâ¿¡ ´ëÇØ Á¶»ç ºÐ¼®Çϰí, °¢ ±¹°¡ÀÇ Ä¡·á °èÃþ, Áõ»ó ¹ßÁõ, Áø´Ü, Ä¡·á µ¿Ç⡤°úÁ¦, Ä¡·á ¼±ÅÃÁö, ÀÌ¿ë °¡´ÉÇÑ ¾àÁ¦ Ŭ·¡½º, ÁÖ¿ä ºê·£µå¿¡ ´ëÇÑ Æò°¡, ó¹æ¿¡ ¹ÌÄ¡´Â °¢Á¾ ¿µÇâ ¿äÀÎ µî¿¡ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
°ñ´Ù°øÁõ ¹× ´ë»ç¼º °ñÁúȯ ½ÃÀå : 2008-2023³â Osteoporosis & Bone Metabolism Disorders Market 2008-2023 Management Report |
|
Pub Time : 2008/08 Published by : Visiongain |
| ´ë»ç¼º °ñÁúȯÀÇ °³¿ä¿Í ÇÔ²² ¼¼°è ½ÃÀå µ¿Çâ°ú Áö¿ªº° ½ÃÀå°³¿ä, 2023³â±îÁöÀÇ ½ÃÀå È®´ë ¿¹Ãø µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. |
|
¹Ì±¹ÀÇ °ñ´Ù°øÁõ ½ÃÀå U.S. Osteoporosis Market |
|
Pub Time : 2008/06 Published by : Frost & Sullivan |
| ¹Ì±¹ °ñ´Ù°øÁõ ½ÃÀåÀÇ 2004-2014³â°£ ÁúȯÀÇ °³¿ä, ±â¼ú µ¿Çâ, ¼öÀÍ ¿¹Ãø, ½ÃÀåÁ¡À¯À² ºÐ¼®, ½ÃÀåÀÇ °úÁ¦, ÃËÁø¿äÀÎ ¹× ¾ïÁ¦¿äÀÎ µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. |
|
°ñÀüÀÌ ½ÃÀåÀÇ µ¿Çâ Stakeholder Opinions: Bone Metastases - Impending patent expiries may help make or break newer agents |
|
Pub Time : 2008/03 Published by : Datamonitor |
| °ñÀüÀÌÀÇ ¸ÞÄ¿´ÏÁò, ¿ªÇÐ µ¥ÀÌÅÍ, ±âÁ¸ Ä¡·áÀÇ ¼±ÅÃÁö, ¹ÌÃæÁ· ¿ä±¸, ÆÄÀÌÇÁ¶óÀÎ ÀǾàǰÀÇ ºÐ¼® µî °ñÀüÀÌÀÇ ÁÖ¿ä ¹®Á¦¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. |
|
°ñ´Ù°øÁõ Ä¡·áµ¿Çâ Osteoporosis Therapeutics |
|
Pub Time : 2008/03 Published by : Global Industry Analysts, Inc. |
| °ñ´Ù°øÁõ Ä¡·á °³¿ä¿Í Á¦Ç°°³¿ä, ÃÖ±Ù ¾÷°è Ȱµ¿ ¹× ÇâÈÄ ½ÃÀå ¿¹Ãø µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. |
|
Target Product Profile : ´Ù¹ß¼º°ñ¼öÁ¾ Target Product Profiles: Physician Insights on Key Attributes - Multiple Myeloma |
|
Pub Time : 2008/03 Published by : Decision Resources, Inc. |
| ´Ù¹ß¼º°ñ¼öÁ¾ÀÇ ¹ßº´ÀÎÀÚ ¹× º´Å»ý¸®¸¦ Á¶»ç ºÐ¼®Çϰí, ¾àÁ¦°³¹ß ȯ°æ°ú ÀÓ»ó½ÃÇè ´ã´çÀÇÀÇ ÁÖ¸ñ »çÇ×, Àǻ簡 Áß¿ä½ÃÇÏ´Â ÀÓ»ó½ÃÇè Æò°¡ Ç׸ñ, ÇâÈÄ 10³â°£ ´ëÃ³ÇØ¾ß ÇÒ ¹ÌÃæÁ·¿ä±¸ µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. |
|
´Ù¹ß¼º°ñ¼öÁ¾ : º¹ÇÕ¾àÁ¦ Ä¡·áÀÇ »õ·Î¿î Ç¥Àû ޱ¸ Stakeholder Opinions: Multiple Myeloma - Exploring new targets for multiple drug therapy |
|
Pub Time : 2007/12 Published by : Datamonitor |
| ´Ù¹ß¼º°ñ¼öÁ¾ÀÇ °³¿ä ¹× ÇöÀçÀÇ Ä¡·á¹ý, ÃæÁ·µÇÁö ¾ÊÀº ¿ä±¸, ¿¬±¸°³¹ß µ¿Çâ ¹× Á¦3»ó ÀÓ»ó½ÇÇè ´Ü°èÀÎ ¾àÁ¦ µî¿¡ ´ëÇØ ¹Ì±¹ ¹× EUÀÇ ¿ÀÇǴϾ𠸮´õÀÇ °ßÇØ¸¦ ÷ºÎÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
Áß±¹ÀÇ ´ë°üÀý Àç°Ç ÀÓÇöõÆ® ½ÃÀå : 2007 Chinese Markets for Large-Joint Reconstructive Implants 2008 |
|
Pub Time : 2007/12 Published by : Millennium Research Group |
| Áß±¹ÀÇ ´ë°üÀý Àç°Ç(°í°üÀý ¹× ½½°üÀý) ÀÓÇöõÆ® ½ÃÀåÀ» »ó¼¼È÷ Á¶»ç ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
ÀεµÀÇ ´ë°üÀý Àç°Ç ÀÓÇöõÆ® ½ÃÀå : 2007 Indian Markets for Large-Joint Reconstructive Implants 2008 |
|
Pub Time : 2007/12 Published by : Millennium Research Group |
| ÀεµÀÇ ´ë°üÀý Àç°Ç(°í°üÀý ¹× ½½°üÀý) ÀÓÇöõÆ® ½ÃÀåÀ» »ó¼¼È÷ Á¶»ç ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
¹Ì±¹ÀÇ Ã´Ãß°íÁ¤ ±â¼ú ½ÃÀå : 2008 US Markets for Spinal Fusion Technologies 2008 |
|
Pub Time : 2007/12 Published by : Millennium Research Group |
| ÀÎüÀÇ Ã´Ãß±¸Á¶ °³¿ä, ¹Ì±¹ÀÇ Ã´Ãß°íÁ¤ ½ÃÀå, ƯÈ÷ Á¾·¡ÀÇ Èä¿äÃߤý°æÃß ÀÓÇöõÆ® ½ÃÀå ¹× Ã¼°£ µð¹ÙÀ̽º ½ÃÀåÀ» »ó¼¼È÷ Á¶»ç ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
ºê·£µå ¹× Àü·« : °ñ´Ù°øÁõ Brands & Strategies: Osteoporosis |
|
Pub Time : 2007/10 Published by : Decision Resources, Inc. |
| ¹Ì±¹, À¯·´, ÀϺ»ÀÇ °ñ´Ù°øÁõ Ä¡·á¾à ½ÃÀåÀ» ºÐ¼®ÇÏ°í ´ë±Ô¸ð °æÇÕ±â¾÷ÀÇ µ¿Çâ ¹× ¸Å»ó, SWOT ºÐ¼®, ÁÖ¿ä ºê·£µå¿¡ ´ëÇÑ ÀÇ»çÀÇ °ßÇØ, 2006³â¿¡¼ 2011³â±îÁöÀÇ ½ÃÀå ¿¹Ãø µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. |
|
À¯·´ÀÇ º¯Çü¼º °üÀý¿° ½ÃÀå European Osteoarthritis Markets |
|
Pub Time : 2007/06 Published by : Frost & Sullivan |
| º¯Çü¼º °üÀý¿°ÀÇ º´¿ø ÇöȲ, ÀÌȯÀ², ÇöÀçÀÇ Ä¡·á¹ý, È÷¾Ë·ç·Ð»ê(HYALURONIC) ½ÃÀåÀÇ ºÐ¼®, ±â¼úÀû ÀüÁø µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. |
|
°ñ´Ù°øÁõ ½ÃÀ嵿Çâ Commercial Insight: Osteoporosis - Risk management and reformulation offer best defense against generic onslaught |
|
Pub Time : 2007/06 Published by : Datamonitor |
| °ñ´Ù°øÁõ Ä¡·á °³¿ä, 2016³â±îÁöÀÇ ¸ÅÃâ ¿¹Ãø, ÁÖ¿ä 7°³±¹ ½ÃÀåÀÇ ½ÃÀå ±âȸ¿Í À§Çù, ¼öÀÍ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä À̺¥Æ®, ¼ö¸í Áֱ⠰ü¸®¿¡ °üÇÑ »ç·Ê¿¬±¸ µîÀ» ÀüÇØµå¸³´Ï´Ù. |
|
¹Ì±¹ÀÇ Ã´¼ö¼ö¼ú ½ÃÀå U.S. Spinal Surgery Markets |
|
Pub Time : 2007/05 Published by : Frost & Sullivan |
| ô¼ö ¼ö¼ú ¾÷°èÀÇ °³¿ä¿Í ºÐ¾ßº° ¼öÀÍ, ½ÃÀå Á¡À¯À²°ú ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¿äÀÎ µîÀ» ÀüÇØµå¸³´Ï´Ù. |
|
DEXAÀÇ Ãֽе¿Çâ Advances in DEXA |
|
Pub Time : 2007/03 Published by : Technical Insights, Inc. |
| DEXA °ü·Ã Ãֽе¿Çâ, °ñ´Ù°øÁõ µîÀÇ Áúº´ Áø´Ü/Ä¡·á ºÐ¾ß¿¡¼ÀÇ ÀÀ¿ë µ¿Ç⠵ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. |
|
¹Ì±¹ÀÇ ´Ù¹ß¼º °ñ¼öÁ¾ ½ÃÀå U.S. Multiple Myeloma Market |
|
Pub Time : 2007/03 Published by : Frost & Sullivan |
| ¹Ì±¹ ´Ù¹ß¼º °ñ¼öÁ¾ ½ÃÀåÀÇ ÇöÀç ¹× ±Þ¼ÓÇÑ º¯ÈÀÇ µ¿Çâ, 2013³â±îÁöÀÇ ¼öÀÍ ¿¹Ãø, ȯÀÚ µ¿Çâ ¿¹Ãø, ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× Á¦Ç°º° ¼öÀÍ ¿¹Ãø µîÀ» Á¦°øÇÕ´Ï´Ù. |
|
º¯Çü¼º°üÀýÁõ ½ÃÀå µ¿Çâ Commercial Insight: Osteoarthritis - Market sees steady growth |
|
Pub Time : 2006/12 Published by : Datamonitor |
| º¯Çü¼º°üÀýÁõ Ä¡·á½ÃÀåÀÇ 2015³â±îÁöÀÇ ¸ÅÃâ ¿¹Ãø, ÁÖ¿ä ½ÃÀå¿¡¼ º¯Çü¼º°üÀýÁõÀÇ ÇöÀç ¹× Àå·¡ÀÇ ±âȸ¿Í À§Çù, COX-2 ÀúÇØÁ¦ÀÇ ±¤°í ¹× ¸¶ÄÉÆÃ¿¡ °üÇÑ ÄÉÀ̽º½ºÅ͵ð µîÀ» Á¦°øÇÕ´Ï´Ù. |
|
°ñ °üÀý¿° µ¿Çâ Pipeline Insight: Osteoarthritis - The Wait for a DMOAD Continues |
|
Pub Time : 2006/11 Published by : Datamonitor |
| °ñ °üÀý¿° Ä¡·á¾àÀÇ °³¹ß µ¿Çâ°ú 2015³â±îÁöÀÇ ¾àÁ¦ ¸ÅÃâ ¿¹Ãø, °æÇÕ ºÐ¼®, ȯÀÚ µ¿Çâ ¹× ¹Ì±¹/EU 5°³±¹/ÀϺ»ÀÇ ¹Ì´Þ¼º ¼ö¿ä, ±â¾÷ Æ÷Æ®Æú¸®¿À ¹× ½ÃÀå ¼ö¿ä¿¡ ±Ù°ÅÇÑ ¶óÀ̼¾½Ì ±âȸ µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. |
|
Forteo£ºÆ÷È »óÅÂÀÇ ½ÃÀå¿¡ ´ëÇÑ È¹±âÀû Ä¡·á¹ýÀÇ µµÀÔ »ç·Ê¿¬±¸ Forteo: A Case Study in Launching a Breakthrough Therapy in a Saturated Market |
|
Pub Time : 2006/10 Published by : Decision Resources, Inc. |
| °ñ´Ù°øÁõÀÇ °³¿ä¿Í ÇöÀçÀÇ Ä¡·á¹ý, ÀÌ¿ëµÇ°í ÀÖ´Â ¾àÁ¦ µ¿Çâ, Forteo °ü·Ã °³¹ß µ¿Çâ ¹× Àΰ¡, ½ÃÀå Âü°¡, ½ÇÀûÀ» Æ÷ÇÔÇÑ »ç·Ê¿¬±¸¿Í ±³ÈÆ µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. |
|
ôÃß ½ÃÀåÀÇ ½ÅÈï ±â¼ú Emerging Technologies for the Spine Market |
|
Pub Time : 2006/09 Published by : Technical Insights, Inc. |
| º» º¸°í¼´Â ôÃß ½ÃÀåÀÇ ½ÅÈï ÀÇ·á ±â±â ±â¼ú°ú ±×°ÍÀÌ ÀÇ·á ½ÃÀå¿¡ ¹ÌÄ£ ¿µÇâ¿¡ ´ëÇÏ¿© ÀüÇØµå¸³´Ï´Ù. |
|
¹Ì±¹ÀÇ °ñ ¼ºÀå ¹× Ã´Ãß °íÁ¤ ÀÚ±Ø ÀåÄ¡ ½ÃÀå U.S. Bone Growth & Spinal Fusion Stimulators Markets |
|
Pub Time : 2006/08 Published by : Frost & Sullivan |
| ¹Ì±¹¿¡¼ °ñ ¼ºÀå ¹× Ã´Ãß °íÁ¤ ÀÚ±Ø ÀåÄ¡´Â ±×´ÙÁö »ç¿ëµÇÁö ¾Ê¾Ò½À´Ï´Ù. ±×·¯³ª °ñÀý ȯÀÚ³ª ôÃß °íÁ¤ÀÌ ÇÊ¿äÇÑ È¯ÀÚ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó µ¿½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. |
|
½Å¾à µ¿Ç⣺ ±Ù°ñ°ÝÁúȯ Ä¡·á¾à New Drug Futures: Musculoskeletal |
|
Pub Time : 2006/05 Published by : Espicom Business Intelligence |
| °üÀý ·ù¸¶Æ¼Áò ¹× °ñ´Ù°øÁõ¿¡ ÃÊÁ¡À» ¸ÂÃß¾î, ±Ù°ñ°ÝÁúȯ Ä¡·á¾à ½ÃÀå µ¿Çâ°ú ¸ÅÃâ ÃßÀÌ, ȯÀÚ Àα¸, ÇöÀç Ä¡·á °³¿ä, °¢ Âü°¡ ±â¾÷ °³¿ä¿Í ¾àÁ¦¿¡ °üÇÑ »ó¼¼ µ¥ÀÌÅÍ µîÀ» Á¦°øÇÕ´Ï´Ù. |
|
±Ù°ñ°Ý Áúȯ Ä¡·á¾àÀÇ ÆÄÆ®³Ê °Å·¡/Á¦ÈÞ µ¿Çâ Partneringdesk Deals and alliances in musculoskeletal diseases |
|
Pub Time : 2006/04 Published by : Pharmalicensing Ltd. |
| 2001³â 1¿ùºÎÅÍ 2006³â 3¿ù±îÁöÀÇ ±Ù°ñ°Ý Áúȯ Ä¡·á¾àÀÇ 370°Ç ÆÄÆ®³Ê °Å·¡ ¹× Á¦ÈÞ µ¿Çâ, ÇöÀç Ȱµ¿ÁßÀÎ ÆÄÆ®³Ê µ¿Çâ, °æÀï ºÐ¼®, º¥Ä¡¸¶Å·, ÁÖ¿ä 25°³»çÀÇ ÇÁ·ÎÆÄÀϵ ´ëÇØ ´ë·« ¾Æ·¡¿Í °°Àº ±¸¼ºÀ¸·Î Á¤¸®Çß½À´Ï´Ù. |
|
º¯Çü¼º °üÀýÁõ Ä¡·á¿¡ ´ëÇÑ ¿ÀÇǴϾ𠸮´õÀÇ °ßÇØ Stakeholder Opinions: Osteoarthritis - Preconceptions Damage Awareness and Treatments |
|
Pub Time : 2006/03 Published by : Datamonitor |
| ÁÖ¿ä 7°³ ½ÃÀå¿¡¼ ¿¬·É/¼ºº°¿¡ ÀÇÇÑ È¯ÀÚ¼öÀÇ Æò°¡, ÀÇ»ç/ȯÀÚÀÇ ÁöÁöÀÚ/¿¬±¸ °úÇÐÀÚ µîÀÇ ¿ÀÇǴϾ𠸮´õÀÇ °ßÇØ, º¯Çü¼º °üÀýÁõ Ä¡·á/¿¬±¸¿¡ ÀÓÇÏ´Â ±¤¹üÀ§ÇÑ Àü¹®°¡¿¡ ´ëÇÑ ÇöÀçÀÇ ÃæÁ·µÇÁö ¾Ê°í ÀÖ´Â ¿ä±¸¿¡ ´ëÇÑ Á¶»ç, ÇöÀçÀÇ Ä¡·áÀû ³íÀï°ú °³¹ß ÆÄÀÌÇÁ¶óÀο¡ ÀÖ¾î¼ÀÇ ½Å±Ô ¿ä¹ý µî¿¡ ´ëÇØ Á¶»çºÐ¼®ÇÏ¿´½À´Ï´Ù. |
|
¾à³â¼º °üÀý¿° Juvenile Arthritis - A Niche In The Market |
|
Pub Time : 2005/12 Published by : Datamonitor |
| ÁÖ¿äÇÑ ¾à³â¼º °üÀý¿°À» Á¤ÀÇ, ºÐ¼®, ÁÖ¿ä Ä¡·á¾à°ú ±× ¿ë¹ý ¼³¸í, ÃÖ±Ù Ä¡Çè µ¥ÀÌÅÍ, Ä¡·á °¡ÀÌµå ¶óÀÎÀÇ ¿ä¾à, Àå·¡ÀÇ °¢ Ä¡·á¾àÀÇ ÀÚ¸®¸Å±è, ¶óÀÌÇÁ »çÀÌŬ °ü¸® Àü·«µîÀ» Æ÷ÇÔÇÏ¿© µµÇ¥¿Í ÇÔ²² ´ë·« ¾Æ·¡¿Í °°Àº ±¸¼ºÀ¸·Î ÀüÇØµå¸³´Ï´Ù. |
|
¾ÏÄ¡·á¿¡ ÀÖ¾î¼ Bisphosphonates ¹× ±âŸ °ñ Ä¡·á¾àÀÇ È¿´É Bisphosphonates and Other Bone-Targeting Compounds in the Treatment of Cancer |
|
Pub Time : 2005/12 Published by : Decision Resources, Inc. |
| Bisphosphonates¸¦ ÀÌ¿ëÇÑ Ä¡·áÀÇ °³¿ä¿Í ÇöÀç ÀÔ¼ö°¡´ÉÇÑ ¾àÁ¦ ¹× ±× ¾ÈÀü¼º, À¯¹æ¾Ï ¹× Àü¸³¼±¾Ï ȯÀÚÀÇ °ñ¿¡ÀÇ ÀüÀÌ ¹× °ñ·® °¨¼Ò Ä¡·á¸¦ À§ÇÑ ÀÌ ¾àÁ¦ÀÇ È¿´É, °ñÀÇ Áúȯ¿¡ ´ëÇÑ ½ÅÈï ºñBisphosphonates¾àÀÇ ÇÁ·ÎÆÄÀÏ µî¿¡ ´ëÇØ ÀüÇØµå¸³´Ï´Ù. |
|
°ñ´Ù°øÁõ Ä¡·áÀÇ ÆÄ¾ÆÇÁ¶óÀÎ(Pipeline) ºÐ¼® Pipeline Insight: Osteoporosis - The Science of Compliance |
|
Pub Time : 2005/10 Published by : Datamonitor |
| °ñ´Ù°øÁõÀÇ ¿ªÇÐ, °¢ Áö¿ªÀÇ È¯ÀÚ¼ö, Æ´»õ Àα¸¿Í °³¼± ¿ä±¸, Èı⠰³¹ß¾àÀÇ »ó¼¼ÇÑ ÇÁ·ÎÈÀÏ, ÁÖ¿ä±â¾÷¿¡ ÀÇÇÑ ¿¬±¸ °³¹ß Ȱµ¿, 2015³â¿¡ °ÉÄ£ ¸ÅÃâ ¿¹Ãøµî¿¡ ´ëÇÏ¿© µµÇ¥¿Í ÇÔ²² ´ë·« ¾Æ·¡ÀÇ ±¸¼ºÀ¸·Î ÀüÇØµå¸³´Ï´Ù. |
|
¹Ì±¹ ¹× ¼À¯·´ ½ÃÀåÀÇ »À ´ëüÀç ½ÃÀå ºÐ¼®°ú ¿¹Ãø U.S and Western European Bone Graft Substitute Market |
|
Pub Time : 2005/06 Published by : Nelesh Patel |
| º» º¸°í¼´Â °ñÀÌ½Ä ´ëüÀç Á¦Ç°ÀÇ »ó¼¼ ºÐ¼®°ú ºñ±³, °ñÀÌ½Ä ´ëüÀç ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¿äÀÎ, ±â¼ú ¹× ºñÁî´Ï½º»óÀÇ °úÁ¦, ¹Ì±¹ ¹× ¼À¯·´ ½ÃÀåÀÇ ±Ô¸ð(¼öÀÍ, ÃâÇÏ·®)¿Í ÇâÈÄ ¿¹Ãø µîÀ» ´ë·« ¾Æ·¡¿Í °°Àº ±¸¼ºÀ¸·Î ÀüÇØ µå¸³´Ï´Ù. |
|
¿¬Á¶Á÷ Àç»ý¼öº¹ ½ÃÀåÀÇ °æÀï µ¿Çâ Competitor Insights for Soft Tissue Repair |
|
Pub Time : 2005/06 Published by : Millennium Research Group |
| ¿¬Á¶Á÷ Àç»ý¼öº¹ ½ÃÀåÀÇ µ¿Çâ °æÀï ºÐ¼®°ú ±×°Í¿¡ Âü°¡ÇÏ´Â ÁÖ¿ä ±â¾÷ÀÇ °³¿ä, Á¦Ç° °³¿ä, ¼¼°è ¸ÅÃâ ½ÇÀû, SWOT ºÐ¼®°á°ú µî, ´ë·« ¾Æ·¡¿Í °°Àº ±¸¼ºÀ¸·Î Á¤¸®Çß½À´Ï´Ù. |
|
Á¤Çü¿Ü°ú¿ë »ýüÀûÀÀÀç·á ½ÃÀåÀÇ °æÇÕ µ¿Çâ Global Competitor Insights for Orthopedic Biomaterials |
|
Pub Time : 2005/05 Published by : Millennium Research Group |
| Á¤Çü¿Ü°ú¿ë »ýüÀûÀÀÀç·á ½ÃÀåÀÇ °³¿ä¿Í, ÀÌ ½ÃÀå¿¡ Âü°¡ÇÏ´Â ÁÖ¿ä ±â¾÷ÀÇ °³¿ä, Á¦Ç°°³¿ä, À繫Àü·« ¹× SWOT ºÐ¼® °á°ú µîÀ» ¾Æ·¡¿Í °°ÀÌ Á¤¸®ÇÏ¿´½À´Ï´Ù. |
|
ÀϺ»ÀÇ Àç»ý ÀÓÇöõÆ® ½ÃÀå: 2005³â Japanese Markets for Reconstructive Implants 2005 |
|
Pub Time : 2005/05 Published by : Millennium Research Group |
| °üÀý Çü¼º¼úÀÇ °³¿ä¿Í ÇÔ²² ÀϺ»ÀÇ Àç»ý ÀÓÇöõÆ® ½ÃÀå¿¡ ´ëÇØ ¹«¸ ÀÓÇöõÆ®, Ç㸮 ÀÓÇöõÆ®, ¾î±ú ÀÓÇöõÆ®, ÆÈ²ÞÄ¡ ÀÓÇöõÆ®, °ñ½Ã¸àÆ® °¢°¢ÀÇ ½ÃÀå¿¡ °üÇÑ ¿¹Ãø Á¶»ç, °æÀï ºÐ¼®µîÀ» Æ÷ÇÔÇÏ¿© ´ë·« ¾Æ·¡¿Í °°Àº ±¸¼ºÀ¸·Î Á¤¸®Çß½À´Ï´Ù. |
|
À¯·´ÀÇ Àç»ý ÀÓÇöõÆ® ½ÃÀå: 2005³â European Markets for Reconstructive Implants 2005 |
|
Pub Time : 2005/02 Published by : Millennium Research Group |
| °üÀý Çü¼º¼úÀÇ °³¿ä¿Í ÇÔ²² À¯·´ÀÇ Àç»ý ÀÓÇöõÆ® ½ÃÀåÀÇ °³¿ä ¹× ÇÁ¶û½º, µ¶ÀÏ, ÀÌÅ»¸®¾Æ, ¿µ±¹ °¢±¹ÀÇ ½ÃÀå µ¿Çâ°ú °æÀï ºÐ¼®, ÀÓÇöõÆ® µ¿Çâ ¹× ÇâÈÄ ¹ßÀü ¿¹Ãøµî¿¡ ´ëÇØ ´ë·« ¾Æ·¡¿Í °°Àº ±¸¼ºÀ¸·Î Á¤¸®Çß½À´Ï´Ù. |
|
¹Ì±¹ÀÇ °ñ´Ù°øÁõ Ä¡·á½ÃÀå U.S. Osteoporosis Therapeutics Markets |
|
Pub Time : 2005/01 Published by : Frost & Sullivan |
| º» º¸°í¼´Â ºñ½ºÆ÷½ºÆ÷³×ÀÌÆ®, SERM(¼±ÅÃÀû ¿¡½ºÆ®·Î°Õ ¼ö¿ëü Á¶ÀýÁ¦), calcitonin(Ä®½ÃÅä´Ñ), PTH(ºÎ°©»ó¼± È£¸£¸ó) µî °ñ´Ù°øÁõ Ä¡·á¿ë ºñÈ£¸£¸ó°è 󹿾àÀÇ ¹Ì±¹ ½ÃÀåÀ» Á¶»çÇϰí, Ä¡·á¾àº°·Î ȯÀÚ¼ö¿Í ¸ÅÃâÀÇ Àå·¡¿¹Ãø µîÀ» ´ë·« ¾Æ·¡¿Í °°Àº ±¸¼ºÀ¸·Î ÀüÇØ µå¸³´Ï´Ù. |
|
¼¼°èÀÇ °ñ¹ÝÀúÀç°Ç ½ÃÀå Global Markets for Pelvic Floor Reconstruction |
|
Pub Time : 2004/11 Published by : Millennium Research Group |
| º» º¸°í¼´Â ¹Ì±¹/À¯·´/ÀϺ»ÀÇ °ñ¹ÝÀúÀç°Ç ½ÃÀå¿¡¼ÀÇ Ã³Ä¡ °Ç¼ö, Àç°Ç Àç·á ŸÀÔ°ú °°Àº »ó¼¼ÇÑ ½ÃÀå ºÐ¼®°ú Àå·¡ ¿¹Ãø, ½ÃÀå ¹ßÀü/ÀúÇØ ¿äÀÎ µîÀ» Á¶»ç ºÐ¼®ÇØ ´Ù¼öÀÇ µµÇ¥¸¦ Æ÷ÇÔÇÏ¿© 102ÆäÀÌÁö¿¡ °ÉÃÄ ´ë·« ¾Æ·¡¿Í °°Àº ±¸¼ºÀ¸·Î ÀüÇØ µå¸³´Ï´Ù. |
|
Á¤Çü¿Ü°ú¿ë ¾àÁ¦/ÀÓÇ÷£Æ®/ÀåÄ¡ ½ÃÀå Orthopedic Drugs, Implants and Devices |
|
Pub Time : 2004/10 Published by : BCC Research |
| º» º¸°í¼´Â Á¤Çü¿Ü°ú¿ë ¾àÁ¦/ÀÓÇ÷£Æ®/ÀåÄ¡ÀÇ Á¾·ù, 2009³â±îÁöÀÇ °¢ ±â¼ú ÆÇ¸Å °ßÀû°ú ½ÃÀå ¿¹Ãø, Á¦Á¶¾÷ÀÚ/½ÅÁ¦Ç°/½ÃÀå Á¡À¯À² Á¤º¸, Ãֽе¿Çâ°ú ¹ßÀüÀ» Æ÷ÇÔÇÑ ±â¼úÀû ¹®Á¦, Á¤ºÎ ±ÔÁ¦, 2000-2004³â°£ÀÇ ¾àÁ¦/ÀÓÇ÷£Æ®/ÀåÄ¡ÀÇ ½ÂÀÎ ¸®½ºÆ®, ƯÇã¿Í ±× Á߿伺 µî¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇÏ¿© Á¦°øÇØ µå¸³´Ï´Ù. |
|
¼¼°èÀÇ °ñ´Ù°øÁõ°ú HRT ½ÃÀå Commercial Insight: Osteoporosis and HRT - Novel Osteoporosis Drugs Counter Generic Threat While HRT Players Regroup and Move Forward |
|
Pub Time : 2004/10 Published by : Datamonitor |
| º» º¸°í¼´Â ¼¼°è ÁÖ¿ä 7°³±¹ ½ÃÀåÀÇ ¿©¼º ¹× ³²¼º °ñ´Ù°øÁõ ¿ªÇÐ, WHI(Women¡¯s Health Initiative)ÀÇ ¿µÇâ, ±¹°¡º° Àå·¡ ½ÃÀå ¿¹Ãø µîÀÇ Á¤º¸¸¦ Á¦°øÇϰí ÀÖÀ¸¸ç, 21°³ÀÇ µµÇ¥¸¦ Æ÷ÇÔÇÑ Àüü 78ÆäÀÌÁöÀÇ ´ë·«ÀûÀÎ ±¸¼ºÀº ´ÙÀ½°ú °°½À´Ï´Ù. |
|
¹Ì±¹ÀÇ °üÀý¿° Ä¡·á ½ÃÀå U.S. Arthritis Therapies Markets |
|
Pub Time : 2004/05 Published by : Frost & Sullivan |
| º» º¸°í¼´Â ¹Ì±¹ÀÇ °üÀý¿° Ä¡·á ½ÃÀå Àüü ¹× °¢ °ü·Ã ½ÃÀ壨BRM, NSAID ¹× DMARD£©ÀÇ °³¿ä, µ¿Çâ, ¼ö¿ä ¹× ¼öÀÍ ºÐ¼®, ½ÃÀå Á¡À¯À²À» Æ÷ÇÔÇÑ °æÇÕ ºÐ¼® µîÀ» ´ë·« ¾Æ·¡¿Í °°Àº ±¸¼ºÀ¸·Î ÀüÇØ µå¸³´Ï´Ù. |
|
ôÃß ¼ö¼úÀÇ ³í Ç»Àü(Non-fusion) ±â¼ú ½ÃÀå U.S. & Asia Markets for Non-fusion Technologies in Spine Procedures |
|
Pub Time : 2004/04 Published by : Frost & Sullivan |
| º» º¸°í¼´Â ôÃß ¼ö¼ú¿¡ °üÇÑ °¢ ½ÃÀå ºÎºÐÀ» »ó¼¼ÇÏ°Ô ºÐ¼®, Âü¿© ±â¾÷ÀÇ °Á¡°ú ¾àÁ¡, ô¼ö ¿Ü°úÀÇ¿¡ ´ëÇÑ ¼¼¹ÐÇÑ Á¶»ç¿¡ ±Ù°ÅÇÑ ³í Ç»Àü ôÃß ¼ö¼ú¿ë ÀåÄ¡ÀÇ Àå·¡ ¿¹Ãø, ¼ö¿ä µîÀÇ Á¤º¸¸¦ Á¦°øÇϰí ÀÖÀ¸¸ç, 21°³ µµÇ¥¸¦ Æ÷ÇÔÇÏ¿© ´ë·« ¾Æ·¡¿Í °°Àº ±¸¼ºÀ¸·Î ÀüÇØ µå¸³´Ï´Ù. |
|
¹Ì±¹ÀÇ Ç㸮/¹«¸°üÀýġȯ¼ú ½ÃÀå Commercial Perspectives: US Hip and Knee Replacement - Market surges in new millennium |
|
Pub Time : 2004/01 Published by : Datamonitor |
|
|
°ñ´Ù°øÁõÀÇ ÃֽŠġ·á¾à°ú ½ÃÀå ¿¹Ãø Pipeline Insight: Osteoporosis - Intermittent Dosing and Multiple Indications Drive Market Growth |
|
Pub Time : 2004/01 Published by : Datamonitor |
|
|
¹Ì±¹/¾Æ½Ã¾ÆÀÇ Ã´Ãß °íÁ¤¼ö¼ú¿¡ µû¸¥ °ñÇü¼º ´Ü¹éÁú ½ÃÀå U.S. and Asia Markets for Bone Morphogenic Proteins in Spine Fusion |
|
Pub Time : 2004/01 Published by : Frost & Sullivan |
| º» º¸°í¼´Â ¹Ì±¹°ú ¾Æ½Ã¾ÆÀÇ Ã´Ãß °íÁ¤¼ö¼ú¿¡ µû¸¥ °ñÇü¼º ´Ü¹éÁú(BMP)½ÃÀå¿¡ ´ëÇØ ºÐ¼®ÇÏ¿© ´Ù¸¥ °üÁ¡(°Ç°°ü¸®´Üü, ô¼ö¼ö¼ú ¹× °úÇÐÀÚ)À¸·ÎºÎÅÍ ÃËÁø ¹× ÀåÇØ¿äÀθ¦ Á¦½ÃÇÏ°í ½ÅÈï ¼ºÀå½ÃÀå¿¡ Âü°¡Çϰí ÀÖ´Â ±â±â Á¦Á¶¾÷ÀÚ¿¡ °üÇÏ¿© Àü·«Àû Á¦¾ð¸¦ ÇàÇÏ´Â µî, ´ë·« ¾Æ·¡¿Í °°Àº ±¸¼ºÀ¸·Î ÀüÇØ µå¸³´Ï´Ù. |
|
ÃÖ¼Òħ½À Ç㸮/½½°üÀý À̽ļö¼ú ½ÃÀå Stakeholder Opinions: Minimally Invasive Hip and Knee Replacement - Excitement Winning Out Over Skepticism |
|
Pub Time : 2003/12 Published by : Datamonitor |
|
|
º¯Çü¼º °ñ°üÀý¿° Disease Modifying Osteoarthritis Drugs - The Search for the 'Holy Grail' Continues |
|
Pub Time : 2003/12 Published by : Datamonitor |
|
|
°ñ´Ù°øÁõ ½ÃÀå Stakeholder Insight: Osteoporosis - Poor Disease Awareness and Patient Identification Hinder Market Growth |
|
Pub Time : 2003/11 Published by : Datamonitor |
|
|
|
|